IDH1 and acute myeloid leukemia: Among the compounds that entered in clinical trials, ivosidenib (AG-120) and enasidenib (AG-221) are the only drugs approved by the FDA for the treatment of IDH1- and IDH2-mutated R/R AML, when intensive treatment is precluded [94].